Under terms of the deal, Akili will become a wholly owned subsidiary of Virtual Therapeutics, with Akili shareholders receiving $0.4340 per share of common stock in cash. Virtual Therapeutics and ...

Akili, a company that makes a video game treatment for ADHD, will sell to Virtual Therapeutics for about $34 million, according to a Wednesday regulatory filing. The two companies will merge into a ...

Akili, maker of a video game-like digital therapeutic for children with ADHD, hit the public markets Monday after wrapping up a merger with special-purpose acquisition company Social Capital Suvretta ...

Akili (NASDAQ:AKLI) stock rose ~38% on Wednesday after the company reported results from a trial of video game-based therapy EndeavorRx to treat adults with attention ...

KIRKLAND, Wash. & BOSTON--(BUSINESS WIRE)-- Virtual Therapeutics, a company focused on improving mental health at scale using engaging, immersive games (“Virtual Therapeutics”), today announced that ...

The team at Akili describes its ethos on its website as “establishing a new era of cognitive medicine.” The company writes it “[believes] effective medicine can also be fun and engaging [by] creating ...

BOSTON--(BUSINESS WIRE)--Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, today reported its financial results for the quarter ended September 30, 2022, and provided an update on ...

A year after getting FDA clearance for its video game treatment for ADHD, Akili Interactive CEO Eddie Martucci said he’s happy with the early response from doctors and patients. But the company still ...

BOSTON--(BUSINESS WIRE)--Akili Interactive (“Akili” or “Company"), a leading prescription digital medicine company developing novel treatments for cognitive dysfunction and brain-related conditions, ...